Pharmaceutical Technology Editors

Walmsley will succeed Andrew Witty as CEO of the British drug maker.

CPhI announced the finalists in all 12 categories for the 2016 excellence in pharma awards.

The agency clarifies how FDA determines when a risk evaluation and mitigation strategy is necessary.

GE Healthcare’s GE BioPark Cork will hold four KUBio manufacturing facilities; GE will also collaborate with NIBRT for biopharmaceutical training.

Adaptimmune entered into a manufacturing agreement with PCT for the manufacture of its SPEAR T-cell therapies.

The autoinjector is based on core technology licensed from Bespak.

The company will debut its multi-dosage weight checker at the October show.

CPhI outlines trends from the conference in Seoul.

EMA has recommended halting supply of non-critical drugs from Pharmaceutics International Inc. because of GMP failures.

The agency recommended approval of 11 drugs, including three cancer drugs, in September.

The new treatment for soft tissue sarcoma has been recommended for conditional marketing authorization in the EU.

The agency has recommended marketing authorization for Ibrance in the European Union.

In response to the EpiPen pricing scandal, Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research, clarifies FDA’s role in drug pricing.

Bayer will acquire the agricultural company for $66 billion in an all cash transaction.

Virtus Pharmaceuticals Opco II, LLC is voluntarily recalling batches of hyoscyamine sulfate (0.125mg).

The project aims to address challenges facing the development, manufacture, and delivery of vaccines.

The organization announced the winners of the 2016 awards at a dinner on Sept. 13 in Washington DC.

Allergan will acquire Vitae pharmaceuticals for $639 million.

FDA sent a warning letter to an Illinois compounding pharmacy for violations of the Federal Food, Drug, and Cosmetic Act.

The agency provides a qualified context of use for the biomarker plasma fibrinogen.

The Gx RTF ClearJect syringe is made of cyclic olefin copolymer and is tungsten- and adhesive-free.

The Novelia system has been approved as a packaging component and delivery system of multidose drug product formulated without preservatives.

Catalent will acquire Pharmatek, a San Diego-based manufacturer of oral, injectable, and topical products.

The company voluntarily recalled the product due to detached needles on the syringe in the kit.

As part of a planned process to replace venture-capital financial partners, Suanfarma S.A. has acquired a stake in Idifarma.

Horizon Pharma will acquire Raptor Pharmaceuticals with the transaction expected to close in the fourth quarter of 2016.

The companies launched Onduo, a joint venture focused on developing solutions to assist patients with Type 2 diabetes.

A customer complaint revealed microbial contamination issues affecting lots with expiration dates in late 2018 and early 2019.

Mumbai, the location for its new Indian subsidiary, will also be the site for the company's Uniquity Global Conference on October 6, 2016.

Analysts examine the latest trends in finished dosage forms.